HHS invests $590m in Moderna for mRNA-based pandemic influenza vaccines

TAGS

The U.S. Department of Health and Human Services () has announced a monumental $590 million investment in , aiming to accelerate the development of -based pandemic influenza vaccines. This funding, channeled through the Biomedical Advanced Research and Development Authority (BARDA) under the Rapid Response Partnership Vehicle (RRPV) consortium, reflects a decisive step toward bolstering the nation’s defense against emerging infectious diseases.

With a focus on leveraging Moderna’s proven mRNA platform, the initiative underscores the importance of innovative biotechnology in addressing potential public health emergencies. The programme aims to enhance vaccine readiness for influenza strains, such as H5N1 and H7N9, while expanding mRNA capabilities for broader health threats.

Why is the HHS investing in pandemic influenza vaccine development?

Pandemic influenza continues to pose a global threat, with strains like H5N1 and H7N9 demonstrating the potential to cause widespread outbreaks. HHS Secretary Xavier Becerra emphasised the urgency of this endeavour, highlighting the unpredictability of avian influenza variants and their historical dangers to human health.

“This response has been a top priority for the Biden-Harris Administration and HHS. Accelerating the development of new vaccines will allow us to stay ahead and ensure that Americans have the tools they need to stay safe,” Becerra said.

See also  3M to sell drug delivery business to Altaris Capital for $650m

The focus on pandemic influenza vaccine development is part of a broader strategy to strengthen U.S. pandemic preparedness. Leveraging Moderna’s mRNA platform, which proved pivotal during the pandemic, this initiative aims to deliver adaptable, scalable solutions for both current and future infectious disease threats.

How will Moderna use the $590 million funding?

The funding will enable Moderna to:

  • Develop an H5N1 mRNA influenza vaccine, tailored to circulating strains observed in avian and bovine populations.
  • Conduct a phase 3 clinical trial for an H7N9 influenza vaccine, which could become the first licensed vaccine for this strain.
  • Design and test four additional pandemic influenza vaccines through early-stage trials to assess safety and immunogenicity.

By creating clinical data across multiple influenza subtypes, the programme aims to establish a robust framework for accelerated vaccine development. Assistant Secretary for Preparedness and Response Dawn O’Connell noted that mRNA technology, as demonstrated during the COVID-19 crisis, offers unprecedented speed and precision in vaccine production.

See also  Samsung Biologics to manufacture Moderna’s mRNA-1273 COVID-19 vaccine

“This investment complements existing vaccine technology, allowing us to move faster and better target emerging viruses to protect Americans against future pandemics,” O’Connell stated.

What role does BARDA play in pandemic countermeasure development?

The Biomedical Advanced Research and Development Authority (BARDA) plays a critical role in advancing medical countermeasures through public-private partnerships. Its funding model supports innovation by bridging the gap between research and practical application. The RRPV consortium, established as a 10-year acquisition framework, fosters collaboration between government agencies and industry leaders to address urgent health needs.

BARDA’s Influenza and Emerging Infectious Diseases Division oversees this latest investment, which builds on the agency’s extensive portfolio of medical countermeasures. The division has consistently prioritised technologies with broad applicability, ensuring readiness for diverse health challenges.

Why is mRNA technology pivotal for pandemic preparedness?

Moderna’s success in deploying mRNA technology during the COVID-19 pandemic has demonstrated its versatility and efficiency. Unlike traditional vaccines, mRNA vaccines can be rapidly designed and produced, making them invaluable in responding to rapidly evolving health threats.

See also  Cipla Therapeutics partners with SIGA Technologies for antibacterial drugs

The mRNA platform’s adaptability enables researchers to target specific virus subtypes, such as H5N1 and H7N9, with precision. This technology also simplifies the manufacturing process, allowing for scalable production to meet global demands.

Through this initiative, Moderna aims to enhance its manufacturing capabilities and expand its mRNA portfolio to include multiple influenza subtypes, ensuring a robust response to emerging infectious diseases.

What does this mean for public health in the U.S.?

This investment signals a significant commitment to protecting public health by advancing pandemic preparedness. By prioritising mRNA-based solutions, the U.S. is better positioned to respond to influenza outbreaks with pandemic potential.

The partnership between HHS and Moderna represents a proactive approach to mitigating the risks of future pandemics. It also highlights the importance of government-industry collaboration in addressing global health challenges.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This